Screening for fragile X syndrome: A literature review and modelling study

Health Technology Assessment

Volumn 7, Issue 16, 2003, Pages

  Song, F J ^a   Barton, P ^b   Sleightholme, V ^c   Yao, G L ^b   Fry Smith, A ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b Health Services Management Centre   (United Kingdom)

^c BIRMINGHAM WOMEN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABORTION; CLINICAL PRACTICE; CLINICAL TRIAL; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; ECONOMIC EVALUATION; EMBASE; FAMILY; FETUS DEATH; FETUS WASTAGE; FRAGILE X SYNDROME; GENE MUTATION; GENETIC SCREENING; HEALTH CARE COST; HEALTH PROGRAM; HETEROZYGOTE; HETEROZYGOTE DETECTION; HIGH RISK POPULATION; HUMAN; IATROGENIC DISEASE; LEARNING DISORDER; MEDICAL LITERATURE; MEDLINE; NATIONAL HEALTH SERVICE; POPULATION MODEL; PREGNANCY; PRENATAL DIAGNOSIS; PRENATAL SCREENING; PREVALENCE; QUALITY OF LIFE; REVIEW; SENSITIVITY ANALYSIS; SIMULATION; SPONTANEOUS ABORTION; UNITED KINGDOM; BIOLOGICAL MODEL; ECONOMICS; FEMALE; GENETICS; MALE; METHODOLOGY;

ENGLAND; FEMALE; FRAGILE X SYNDROME; GENETIC TESTING; HETEROZYGOTE DETECTION; HUMANS; MALE; MODELS, GENETIC; PREGNANCY; PREVALENCE; WALES;

EID: 85044702643     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta7160     Document Type: Review

References (125)

1. Murray J, Cuckle H, Taylor G, Hewison J. Screening for fragile X syndrome. Health Technol Assess 1997;1:1-69.
2. Pembrey ME, Barnicoat AJ, Carmichael B, Bobrow M, Turner G. An assessment of screening strategies for fragile X syndrome in the UK. Health Technol Assess 2001;5:1-95.
3. The Office for National Statistics. Key Population and Vital Statistics - Series VS, No. 27. London: The Stationery Office; 202. pp. 1 No. 23.
4. Sherman SL, Morton NE, Jacobs PA, Turner G. The marker (X) syndrome: A cytogenetic and genetic analysis. Ann Hum Genet 1984;48:21-37.
5. Verkerk AJ, Pieretti M, Sutcliffe JS, Fu YH, Kuhl DP, Pizzuti A, et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 1991;65:905-14.
6. Weisman-Shomer P, Cohen E, Fry M. Interruption of the fragile X syndrome expanded sequence d(CGG)(n) by interspersed d(AGG) trinucleotides diminishes the formation and stability of d(CGG)(n) tetrahelical structures. Nucleic Acids Res 2000;28:1535-41.
7. Vintzileos AM, Ananth CV, Fisher AJ, Smulian JC, Day-Salvatore D, Beazoglou T, et al. Economic evaluation of prenatal carrier screening for fragile X syndrome. J Matern-Fetal Med 1999;8:168-72.
8. Wildhagen MF, Van Os TA, Polder JJ, Ten Kate LP, Habbema JD. Explorative study of costs, effects and savings of screening for female fragile X premutation and full mutation carriers in the general population. Commun Genet 1998;1:36-47.
9. Murray J, Cuckle H. Cystic fibrosis and fragile X syndrome: The arguments for antenatal screening [review]. Combinat Chem High Throughput Screening 2001;4:265-72.
10. Kornman L, Chambers H. Pre-Conception and Antenatal Screening for the Fragile Site on the X-Chromosome (protocol for a Cochrane review). Oxford: Update Software, 2001.
11. De Vries BB, Van Den Ouweland AM, Mohkamsing S, Duivenvoorden HJ, Mol E, Gelsema K, et al. Screening and diagnosis for the fragile X syndrome among the mentally retarded: An epidemiological and psychological survey. Collaborative Fragile X Study Group. Am J Hum Genet 1997;61:660-7.
12. De Vries BB, Mohkamsing S, Van Den Ouweland AM, Mol E, Gelsema K, Van Rijn M, et al. Screening for the fragile X syndrome among the mentally retarded: A clinical study. The Collaborative Fragile X Study Group. J Med Genet 1999;36:467-70.
13. Arvio M, Peippo M, Simola KO. Applicability of a checklist for clinical screening of the fragile X syndrome. Clin Genet 1997;52:211-15.
14. Warburton S, Waters J, Davison V. Targeted diagnostic testing for fragile X syndrome (poster 3.36). J Med Genet 2001;38:S63.
15. Drasinover V, Ehrlich S, Magal N, Taub E, Libman V, Shohat T, et al. Increased transmission of intermediate alleles of the FMR1 gene compared with normal alleles among female heterozygotes. Am J Med Genet 2000;93:155-7.
16. Spence WC, Black SH, Fallon L, Maddalena A, Cummings E, Menapace-Drew G, et al. Molecular fragile X screening in normal populations. Am J Med Genet 1996;64:181-3.
17. Toledano-Alhadef H, Basel-Vanagaite L, Magal N, Davidov B, Ehrlich S, Drasinover V, et al. Fragile-X carrier screening and the prevalence of premutation and full-mutation carriers in Israel. Am J Hum Genet 2001;69:351-60.
18. Elango R, Verma IC. Fragile X syndrome among children with mental retardation. Indian J Pediatr 1996;63:533-8.
19. Hou JW, Wang TR, Chuang SM. An epidemiological and aetiological study of children with intellectual disability in Taiwan. J Intellect Disabil Res 1998;42:137-43.
20. Wang YC, Li C, Lin ML, Lin WH, Li SY. Molecular diagnosis of fragile X syndrome and distribution of CGG repeats in the FMR-1 gene in Taiwanese. J Formosan Med Assoc 2000;99:402-7.
21. Zhong N, Ju W, Xu W, Ye L, Shen Y, Wu G, et al. Frequency of the fragile X syndrome in Chinese mentally retarded populations is similar to that in Caucasians. Am J Med Genet 1999;84:191-4.
22. Saha S, Karmakar P, Chatterjee C, Banerjee D, Das S, Dasgupta UB. Fragile X syndrome in Calcutta, India. Ann Clin Biochem 2001;38:264-71.
23. Patsalis PC, Sismani C, Hettinger JA, Holden JJ, Lawson JS, Chalifoux M, et al. Frequencies of 'gray-zone' and premutation-size FMR1 CGG-repeat alleles in patients with developmental disability in Cyprus and Canada. Am J Med Genet 1999;84:195-7.
24. Cora T, Demirel S, Acar A. Chromosomal abnormalities in mentally retarded children in the Konya region - Turkey. Genet Couns 2000;11:53-5.
25. Crawford DC, Meadows KL, Newman JL, Taft LF, Pettay DL, Gold LB, et al. Prevalence and phenotype consequence of FRAXA and FRAXE alleles in a large, ethnically diverse, special education-needs population. Am J Hum Genet 1999;64:495-507.
26. Elbaz A, Suedois J, Duquesnoy M, Beldjord C, Berchel C, Merault G. Prevalence of fragile-X syndrome and FRAXE among children with intellectual disability in a Caribbean island, Guadeloupe, French West Indies. J Intellect Disabil Res 1998;42:81-9.
27. Gerard B, Le Heuzey MF, Brunie G, Lewine P, Saiag MC, Cacheux V, et al. Systematic screening for fragile X syndrome in a cohort of 574 mentally retarded children. Ann Genet 1997;40:139-44.
28. Hagerman RJ, Wilson P, Staley LW, Lang KA, Fan T, Uhlhorn C, et al. Evaluation of school children at high risk for fragile X syndrome utilizing buccal cell FMR-1 testing. Am J Med Genet 1994;51: 474-81.
29. Iqbal MA, Sakati N, Nester M, Ozand P. Cytogenetic diagnosis of fragile X syndrome: Study of 305 suspected cases in Saudi Arabia. Ann Saudi Med 2000;20:214-18.
30. Jacobs PA, Bullman H, Macpherson J, Youings S, Rooney V, Watson A, et al. Population studies of the fragile X: A molecular approach. J Med Genet 1993;30:454-9.
31. Sharma D, Gupta M, Thelma BK. Expansion mutation frequency and CGG/GCC repeat polymorphism in FMR1 and FMR2 genes in an Indian population. Genet Epidemiol 2001;20:129-44.
32. Slaney SF, Wilkie AO, Hirst MC, Charlton R, McKinley M, Pointon J, et al. DNA testing for fragile X syndrome in schools for learning difficulties [see comments]. Arch Dis Childh 1995;72:33-7.
33. Turner G, Robinson H, Laing S, Van Den Berk M, Colley A, Goddard A, et al. Population screening for fragile X. Lancet 1992;339:1210-13.
34. Tzeng CC, Lin SJ, Chen YJ, Kuo PL, Jong YJ, Tsai LP, et al. An effective strategy of using molecular testing to screen mentally retarded individuals for fragile X syndrome. Diagn Mol Pathol 2001;10:34-40.
35. Angel AG, Vidal S, Saldana Y, Del C, V, Angel AM, Macias M, et al. Molecular diagnosis of the fragile X and FRAXE syndromes in patients with mental retardation of unknown cause in Mexico. Ann Genet 2000;43:29-34.
36. Arrieta I, Criado B, Martinez B, Telez M, Nunez T, Penagarikano O, et al. A survey of fragile X syndrome in a sample from Spanish Basque country. Ann Genet 1999;42:197-201.
37. Jara L, Lopez M, Mellado C, Aspillaga M, Avendano I, Blanco R. Clinical and molecular screening for fragile X syndrome in 300 patients with non-specific mental retardation [in Spanish]. Rev Med Chile 1998;126:911-18.
38. Kwon SH, Lee KS, Hyun MC, Song KE, Kim JK. Molecular screening for Fragile X syndrome in mentally handicapped children in Korea. J Korean Med Sci 2001;16:271-5.
39. Mila M, Sanchez A, Badenas C, Brun C, Jimenez D, Villa MP, et al. Screening for FMR1 and FMR2 mutations in 222 individuals from Spanish special schools: Identification of a case of FRAXE-associated mental retardation. Hum Genet 1997;100:503-7.
40. Millan JM, Martinez F, Cadroy A, Gandia J, Casquero M, Beneyto M, et al. Screening for FMR1 mutations among the mentally retarded: Prevalence of the fragile X syndrome in Spain. Clin Genet 1999;56:98-9.
41. Pang CP, Poon PM, Chen QL, Lai KY, Yin CH, Zhao Z, et al. Trinucleotide CGG repeat in the FMR1 gene in Chinese mentally retarded patients. Am J Med Genet 1999;84:179-83.
42. Patsalis PC, Sismani C, Hettinger JA, Boumba I, Georgiou I, Stylianidou G, et al. Molecular screening of fragile X (FRAXA) and FRAXE mental retardation syndromes in the Hellenic population of Greece and Cyprus: Incidence, genetic variation, and stability. Am J Med Genet 1999;84:184-90.
43. Syrrou M, Georgiou I, Grigoriadou M, Petersen MB, Kitsiou S, Pagoulatos G, et al. FRAXA and FRAXE prevalence in patients with nonspecific mental retardation in the Hellenic population. Genet Epidemiol 1998;15:103-9.
44. Tuncbilek E, Alikasifoglu M, Boduroglu K, Aktas D, Anar B. Frequency of fragile X syndrome among Turkish patients with mental retardation of unknown etiology [letter; comment]. Am J Med Genet 1999;84:202-3.
45. Froster-Iskenius U, Felsch G, Schirren C, Schwinger E. Screening for fra(X)(q) in a population of mentally retarded males. Hum Genet 1983;63:153-7.
46. Gerard CL, Guillotte E, Servel F, Barbeau M. Assessment and remediation of communication disorders in children with fragile X syndrome. ANAE - Approche Neuropsychologique des Apprentissages Chez l'Enfant 1997;9:224-6.
47. Haddad LA, Aguiar MJ, Costa SS, Mingroni-Netto RC, Vianna-Morgante AM, Pena SD. Fully mutated and gray-zone FRAXA alleles in Brazilian mentally retarded boys. Am J Med Genet 1999;84:198-201.
48. Hofstee Y, Arinami T, Hamaguchi H. Comparison between the cytogenetic test for fragile X and the molecular analysis of the FMR-1 gene in Japanese mentally retarded individuals. Am J Med Genet 1994;51:466-70.
49. Lantigua-Cruz A, Mora F, Arechaederra M, Rojas I, Morales E, Rodriguez H, et al. Etiological characterization of 512 severely mentally retarded institutionalized patients in Havana. Commun Genet 1999;2:184-9.
50. Mazurczak T, Bocian E, Milewski M, Obersztyn E, Stanczak H, Bal J, et al. Frequency of Fra X syndrome among institutionalized mentally retarded males in Poland. Am J Med Genet 1996;64:184-6.
51. Murray A, Youings S, Dennis N, Latsky L, Linehan P, McKechnie N, et al. Population screening at the FRAXA and FRAXE loci: Molecular analyses of boys with learning difficulties and their mothers. Hum Mol Genet 1996;5:727-35.
52. Murray A, Youings S, Ennis S, Sharrock A, Lewis C, McKechnie N, et al. FRAXA and FRAXE: Prevalence, stability and haplotype studies in over 7000 independent chromosomes (SP-039). Eur J Hum Genet 2000;8(S1):35.
53. Neri G, Sanfilippo S, Pavone L. The fragile X in Sicily: An epidemiological survey. Am J Med Genet 1988;30:665-72.
54. Tan BS, Law HY, Zhao Y, Yoon CS, Ng IS. DNA testing for fragile X syndrome in 255 males from special schools in Singapore. Ann Acad Med Singapore 2000;29:207-12.
55. Turner G, Webb T, Wake S, Robinson H. Prevalence of fragile X syndrome. Am J Med Genet 1996;64:196-7.
56. Webb T, Bundey S, Thake A, Todd J. The frequency of the fragile X chromosome among school children in Coventry. J Med Genet 1986;23:396-9.
57. Butler MG, Singh DN. Clinical and cytogenetic survey of institutionalized mentally retarded patients with emphasis on the fragile-X syndrome. J Intellect Disabil Res 1993;37:131-42.
58. Faradz SMH, Buckley M, Tang LP, Leigh D, Holden JJA. Molecular screening for fragile X syndrome among Indonesian children with developmental disability. Am J Med Genet 1999;83:350-1.
59. Fryns JP, Kleczkowska A, Kubien E, Van Den Berghe H. Cytogenetic findings in moderate and severe mental retardation. A study of an institutionalized population of 1991 patients. Acta Paediatr Scand 1984;313 Suppl:1-23.
60. Kahkonen M, Leisti J, Wilska M, Varonen S. Marker X-associated mental retardation. A study of 150 retarded males. Clin Genet 1983;23:397-404.
61. Limprasert P, Ruangdaraganon N, Sura T, Vasiknanonte P, Jinorose U. Molecular screening for fragile X syndrome in Thailand. Southeast Asian J Trop Med Publ Health 1999;30 Suppl 2:114-18.
62. O'Dwyer J, Holmes J, Mueller R, Taylor G. The prevalence of fragile-X syndrome in an institution for people with learning disability. Psychiatr Genet 1997;7:115-19.
63. Paika IJ, Lai F, McAllister NM, Miller WA. The fragile-X marker survey: Preliminary report on the screening of suspected fragile X syndrome patients at the Fernald State School. Am J Hum Genet 1984;36:108S.
64. Primrose DA, El-Matmati R, Boyd E, Gosden C, Newton M. Prevalence of the fragile X syndrome in an institution for the mentally handicapped. Br J Psychiatry 1986;148:655-7.
65. Tuncbilek E, Alikasifoglu M, Aktas D, Duman F, Yanik H, Anar B, et al. Screening for the fragile X syndrome among mentally retarded males by hair root analysis. Am J Med Genet 2000;95:105-7.
66. Morton JE, Bundey S, Webb TP, MacDonald F, Rindl PM, Bullock S. Fragile X syndrome is less common than previously estimated. J Med Genet 1997;34:1-5.
67. Geva E, Yaron Y, Shomrat R, Ben-Yehuda A, Zabari S, Peretz H, et al. The risk of fragile X premutation expansion is lower in carriers detected by general prenatal screening than in carriers from known fragile X families. Genet Test 2000;4:289-92.
68. Pesso R, Berkenstadt M, Cuckle H, Gak E, Peleg L, Frydman M, et al. Screening for fragile X syndrome in women of reproductive age. Prenatal Diagnosis 2000;20:611-4.
69. Rousseau F, Rouillard P, Morel ML, Khandjian EW, Morgan K. Prevalence of carriers of premutation-size alleles of the FMRI gene - And implications for the population genetics of the fragile X syndrome [see comments]. Am J Hum Genet 1995;57:1006-18.
70. Ryynanen M, Heinonen S, Makkonen M, Kajanoja E, Mannermaa A, Pertti K. Feasibility and acceptance of screening for fragile X mutations in low-risk pregnancies. Eur J Hum Genet 1999;7:212-16.
71. Wenstrom KD, Descartes M, Franklin J, Cliver SP. A five-year experience with fragile X screening of high-risk gravid women. Am J Obstet Gynecol 1999;181:789-92.
72. Larsen LA, Armstrong JS, Gronskov K, Hjalgrim H, Brondum-Nielsen K, Hasholt L, et al. Analysis of FMR1 (CGG)n alleles and FRAXA microsatellite haplotypes in the population of Greenland: Implications for the population of the New World from Asia. Eur J Hum Genet 1999;7:771-7.
73. Larsen LA, Armstrong JS, Gronskov K, Hjalgrim H, Macpherson JN, Brondum-Nielsen K, et al. Haplotype and AGG-interspersion analysis of FMR1 (CGG)(n) alleles in the Danish population: Implications for multiple mutational pathways towards fragile X alleles. Am J Med Genet 2000;93:99-106.
74. Arinami T, Asano M, Kobayashi K, Yanagi H, Hamaguchi H. Data on the CGG repeat at the fragile X site in the non-retarded Japanese population and family suggest the presence of a subgroup of normal alleles predisposing to mutate. Hum Genet 1993;92:431-6.
75. Chen SH, Schoof JM, Buroker NE, Scott CR. The identification of a (CGG)6AGG insertion within the CGG repeat of the FMR1 gene in Asians. Hum Genet 1997;99:793-5.
76. Dawson AJ, Chodirker BN, Chudley AE. Frequency of FMR1 premutations in a consecutive newborn population by PCR screening of Guthrie blood spots. Biochem Mol Med 1995;56:63-9.
77. Reiss AL. Behavioural neurogenetics research: A method for analyzing linkages among gene, brain and behavior. ANAE - Approche Neuropsychologique des Apprentissages Chez l'Enfant 1997;9:213-20.
78. Rousseau F, Morel ML, Levesque S, Dombrowski C, Morgan K. Instability of FMR1 gray-zone and premutation-size alleles identified by screening in the general population. Am J Hum Genet 1997;61:1866.
79. Snow K, Doud LK, Hagerman R, Pergolizzi RG, Erster SH, Thibodeau SN. Analysis of a CGG sequence at the FMR-1 locus in fragile X families and in the general population 414. Am J Hum Genet 1993;53:1217-28.
80. Eichler EE, Holden JJ, Popovich BW, Reiss AL, Snow K, Thibodeau SN, et al. Length of uninterrupted CGG repeats determines instability in the FMR1 gene. Nature Genet 1994;8:88-94.
81. Faradz SM, Pattiiha MZ, Leigh DA, Jenkins M, Leggo J, Buckley MF, et al. Genetic diversity at the FMR1 locus in the Indonesian population. Ann Hum Genet 2000;64:329-39.
82. Holden JJA, Chalifoux M, Wing M, Julien-Inalsingh C, Lawson JS, Higgins JV, et al. Distribution and frequency of FMR1 CGG repeat numbers in the general population. Dev Brain Dysfunct 1995;8:405-7.
83. Sucharov CC, Silva R, Rondinelli E, Moura-Neto RS. Fragile X trinucleotide repeats from a normal population in Rio de Janeiro, Brazil. Hereditas 1999;130:189-90.
84. Patsalis PC, Sismani C, Stylianou S, Ioannou P, Joseph G, Manoli P, et al. Genetic variation and intergenerational FMR1 CGG-repeat stability in 100 unrelated three-generation families from the normal population. Am J Med Genet 1999;84:217-20.
85. Poon PM, Zhao Z, Wu XQ, Ni YX, Pang CP. Rapid analysis of CGG repeat length in the FMR1 gene. Clin Chem Lab Med 2000;38:935-8.
86. Syrrou M, Patsalis PC, Georgiou I, Alamanos Y, Pagoulatos G. Variation in the number of FMR1 microsatellite repeats in three subgroups of the Hellenic population. Hum Biol 1998;70:621-9.
87. Tzeng CC, Cho WC, Kuo PL, Chen RM. Pilot fragile X screening in normal population of Taiwan. Diagn Mol Pathol 1999;8:152-6.
88. Drasinover V, Ehrlich S, Magal N, Taub E, Libman V, Shohat T, et al. Increased transmission of the premutated allele compared to the normal allele in female carriers of the fragile X syndrome. Am J Hum Genet 1999;65:256.
89. Fisch GS, Snow K, Thibodeau SN, Chalifaux M, Holden JJ, Nelson DL, et al. The fragile X premutation in carriers and its effect on mutation size in offspring. Am J Hum Genet 1995;56:1147-55.
90. Moutou C, Vincent MC, Biancalana V, Mandel JL. Transition from premutation to full mutation in fragile X syndrome is likely to be prezygotic. Hum Mol Genet 1997;6:971-9.
91. Ashley-Koch AE, Robinson H, Glicksman AE, Nolin SL, Schwartz CE, Brown WT, et al. Examination of factors associated with instability of the FMR1 CGG repeat. Am J Hum Genet 1998;63:776-85.
92. Nolin SL, Lewis FA, Ye LL, Houck GE, Glicksman AE, Limprasert P, et al. Familial transmission of the FMR1 CGG repeat. Am J Hum Genet 1996;59:1252-61.
93. Milewski M, Zygulska M, Bal J, Deelen WH, Obersztyn E, Bocian E, et al. Analysis of unstable DNA sequence in FMR1 gene in Polish families with fragile X syndrome. Acta Biochim Pol 1996;43:383-8.
94. Murray A, Macpherson JN, Pound MC, Sharrock A, Youings SA, Dennis NR, et al. The role of size, sequence and haplotype in the stability of FRAXA and FRAXE alleles during transmission. Hum Mol Genet 1997;6:173-84.
95. Fu YH, Kuhl DP, Pizzuti A, Pieretti M, Sutcliffe JS, Richards S, et al. Variation of the CGG repeat at the fragile X site results in genetic instability: Resolution of the Sherman paradox. Cell 1991;67:1047-58.
96. Heitz D, Devys D, Imbert G, Kretz C, Mandel JL. Inheritance of the fragile X syndrome: Size of the fragile X premutation is a major determinant of the transition to full mutation. J Med Genet 1992;29:794-801.
97. Kallinen J, Heinonen S, Mannermaa A, Ryynanen M. Prenatal diagnosis of fragile X syndrome and the risk of expansion of a premutation. Clin Genet 2000;58:111-15.
98. Sherman SL, Meadows KL, Ashley AE. Examination of factors that influence the expansion of the fragile X mutation in a sample of conceptuses from known carrier females. Am J Med Genet 1996;64:256-60.
99. Vaisanen ML, Kahkonen M, Leisti J. Diagnosis of fragile X syndrome by direct mutation analysis. Hum Genet 1994;93:143-7.
100. Jallinoja P. Genetic screening in maternity care: Preventive aims and voluntary choices. Sociol Health Illness 2001;23:286-307.
101. Ryynanen M, Kirkinen P, Mannermaa A, Saarikoski S. Carrier diagnosis of the fragile X syndrome - A challenge in antenatal clinics. Am J Obstet Gynecol 1995;172:1236-9.
102. Kallinen J, Marin K, Heinonen S, Mannermaa A, Palotie A, Ryynanen M. Wide scope prenatal diagnosis at Kuopio University Hospital 1997-1998: Integration of gene tests and fetal karyotyping. Bjog 2001;108:505-9.
103. Robinson H, Wake S, Wright F, Laing S, Turner G. Informed choice in fragile X syndrome and its effects on prevalence. Am J Med Genet 1996;64:198-202.
104. Turner G, Robinson H, Wake S, Laing S, Partington M. Case finding for the fragile X syndrome and its consequences [see comments]. BMJ 1997;315:1223-6.
105. Van Rijn MA, De Vries BB, Tibben A, Van Den Ouweland AM, Halley DJ, Niermeijer MF. DNA testing for fragile X syndrome: Implications for parents and family. J Med Genet 1997;34:907-11.
106. Brown WT, Nolin S, Houck GJ, Ding X, Glicksman A, Li SY, et al. Prenatal diagnosis and carrier screening for fragile X by PCR. Am J Med Genet 1996;64:191-5.
107. Meadows KL, Sherman SL. Fragile X syndrome: Examination of issues pertaining to population-based screening. Screening 1996;4:175-92.
108. Cuckle HS, Holding S, Jones R, Groone NP, Wallace EM. Combining inhibin A with existing second-trimester markers in maternal serum screening for Down's syndrome. Prenat Diagn 1996;16:1095-100.
109. Tejada MI, Duran M. Screening for female fragile X premutation and full mutation carriers: A commentary on the work of Wildhagen et al. [1] [2]. Commun Genet 1999;2:49-50.
110. Wildhagen MF, Van Os TA, Polder JJ, Ten Kate LP, Habbema JD. Efficacy of cascade testing for fragile X syndrome. J Med Screening 1999;6:70-6.
111. National Statistics. Mid-2000 Population Estimates. Series PE No. 3. Natural Statistics: London; 2001.
112. Healthcare Resource Groups. Acute Care 97/98. London: Financial Times Healthcare, CHKS Limited; 1997.
113. Public and Professional Policy Committee. Population genetic screening programmes: Proposed recommendations of the European Society of Human Genetics. Eur J Hum Genet 2000;8:998-1000.
114. Carmichael B, Pembrey M, Turner G, Barnicoat A. Diagnosis of fragile-X syndrome: The experiences of parents. J Intellect Disabil Res 1999;43:47-53.
115. McConkie-Rosell A, Spiridigliozzi GA, Sullivan JA, Dawson DV, Lachiewicz AM. Carrier testing in fragile X syndrome: Effect on self-concept. Am J Med Genet 2000;92:336-42.
116. Arrieta I, Gil A, Nunez T, Telez M, Martinez B, Criado B, et al. Stability of the FMR1 CGG repeat in a Basque sample. Hum Biol 1999;71:55-68.
117. Chen TA, Lu XF, Che PK, Ho WK. Variation of the CGG repeat in FMR-1 gene in normal and fragile X Chinese subjects. Ann Clin Biochem 1997;34:517-20.
118. Faradz SM, Buckley M, Lam PT, Leigh D, Holden JJ. Molecular screening for fragile X syndrome among Indonesian children with developmental disability. Am J Med Genet 1999;83:350-1.
119. Giangreco CA, Steele MW, Aston CE, Cummins JH, Wenger SL. A simplified six-item checklist for screening for fragile X syndrome in the pediatric population. J Pediatr 1996;129:611-14.
120. Hecimovic S, Barisic I, Pavelic K. DNA analysis of the fragile X syndrome in an at risk pediatric population in Croatia: Simple clinical preselection criteria can considerably improve the cost-effectiveness of fragile X screening studies. Hum Hered 1998;48:256-65.
121. Ruangdaraganon N, Limprasert P, Sura T, Sombuntham T, Sriwongpanich N, Kotchabhakdi N. Prevalence and clinical characteristics of fragile X syndrome at child development clinic, Ramathibodi Hospital. J Med Assoc Thailand 2000;83:69-76.
122. Jinorose U, Vasiknanonte P, Limprasert P, Brown WT, Panich V. The frequency of fragile X syndrome among selected patients at Songklanagarind Hospital during 1991-1996, studied by cytogenetic and molecular methods. Southeast Asian J Trop Med Pub Health 1997;28 Suppl 3:69-74.
123. Mazzocco MM, Sonna NL, Teisl JT, Pinit A, Shapiro BK, Shah N, et al. The FMR1 and FMR2 mutations are not common etiologies of academic difficulty among school-age children. J Dev Behav Pediatr 1997;18:392-8.
124. Tzeng CC, Tzeng PY, Cho WC, Chen RM. Implication from screening for FMR1 and FMR2 gene mutation in individuals with nonspecific mental retardation in Taiwan. Mol Psychiatry 1999;4:94.
125. Tzeng CC, Tzeng PY, Sun HS, Chen RM, Lin SJ. Implication of screening for FMR1 and FMR2 gene mutation in individuals with nonspecific mental retardation in Taiwan. Diagn Mol Pathol 2000;9:75-80.